Literature DB >> 35704854

Metal-Organic Coordination Polymer for Delivery of a Subunit Broadly Acting Influenza Vaccine.

Meital Eckshtain-Levi1, Cole J Batty1, Liubov M Lifshits1, Brandon McCammitt1, Kathryn M Moore1, Eva A Amouzougan1, Rebeca T Stiepel1, Eliza Duggan2, Ted M Ross3,4, Eric M Bachelder1, Kristy M Ainslie1,5,6.   

Abstract

A zinc-carnosine (ZnCar) metal-organic coordination polymer was fabricated in biologically relevant N-(2-hydroxyethyl)piperazine-N'-ethanesulfonic acid (HEPES) buffer for use as a vaccine platform. In vitro, ZnCar exhibited significantly less cytotoxicity than a well-established zeolitic imidazolate framework (ZIF-8). Adsorption of CpG on the ZnCar surface resulted in enhanced innate immune activation compared to soluble CpG. The model antigen ovalbumin (OVA) was encapsulated in ZnCar and exhibited acid-sensitive release in vitro. When injected intramuscularly on days 0 and 21 in C57BL/6 mice, OVA-specific serum total IgG and IgG1 were significantly greater in all groups with ZnCar and antigen compared to soluble controls. Th1-skewed IgG2c antibodies were significantly greater in OVA and CpG groups delivered with ZnCar for all time points, regardless of whether the antigen and adjuvant were co-formulated in one material or co-delivered in separate materials. When broadly acting Computationally Optimized Broadly Reactive Antigen (COBRA) P1 influenza hemagglutinin (HA) was ligated to ZnCar via its His-tag, significantly greater antibody levels were observed at all time points compared to soluble antigen and CpG. ZnCar-formulated antigen elicited increased peptide presentation to B3Z T cells in vitro and production of IL-2 after ex vivo antigen recall of splenocytes isolated from vaccinated mice. Overall, this work displays the formation of a zinc-carnosine metal-organic coordination polymer that can be applied as a platform for recombinant protein-based vaccines.

Entities:  

Keywords:  carnosine; coordination polymer; hemagglutinin; metal−organic framework (MOF); universal influenza vaccine; vaccine delivery; zinc

Mesh:

Substances:

Year:  2022        PMID: 35704854      PMCID: PMC9495290          DOI: 10.1021/acsami.2c04671

Source DB:  PubMed          Journal:  ACS Appl Mater Interfaces        ISSN: 1944-8244            Impact factor:   10.383


  40 in total

Review 1.  Vaccines: all things considered.

Authors:  Ken S Rosenthal; Daniel H Zimmerman
Journal:  Clin Vaccine Immunol       Date:  2006-08

2.  CpG DNA can induce strong Th1 humoral and cell-mediated immune responses against hepatitis B surface antigen in young mice.

Authors:  C L Brazolot Millan; R Weeratna; A M Krieg; C A Siegrist; H L Davis
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-22       Impact factor: 11.205

3.  A pH-sensitive histidine residue as control element for ligand release from HLA-DR molecules.

Authors:  Olaf Rötzschke; Julie M Lau; Maria Hofstätter; Kirsten Falk; Jack L Strominger
Journal:  Proc Natl Acad Sci U S A       Date:  2002-12-05       Impact factor: 11.205

4.  A robust microparticle platform for a STING-targeted adjuvant that enhances both humoral and cellular immunity during vaccination.

Authors:  Robert D Junkins; Matthew D Gallovic; Brandon M Johnson; Michael A Collier; Rebekah Watkins-Schulz; Ning Cheng; Clément N David; Charles E McGee; Gregory D Sempowski; Ivo Shterev; Karen McKinnon; Eric M Bachelder; Kristy M Ainslie; Jenny P-Y Ting
Journal:  J Control Release       Date:  2017-11-21       Impact factor: 9.776

5.  Enhancement of protein vaccine potency by in vivo electroporation mediated intramuscular injection.

Authors:  Tae Heung Kang; Archana Monie; Lee S-F Wu; Xiaowu Pang; Chien-Fu Hung; T-C Wu
Journal:  Vaccine       Date:  2010-12-04       Impact factor: 3.641

6.  Acid-degradable polyurethane particles for protein-based vaccines: biological evaluation and in vitro analysis of particle degradation products.

Authors:  Eric M Bachelder; Tristan T Beaudette; Kyle E Broaders; Sergey E Paramonov; Jesse Dashe; Jean M J Fréchet
Journal:  Mol Pharm       Date:  2008-08-19       Impact factor: 4.939

7.  Insect cell-expressed hemagglutinin with CpG oligodeoxynucleotides plus alum as an adjuvant is a potential pandemic influenza vaccine candidate.

Authors:  Minqing Gong; Jun Zhou; Chunting Yang; Yao Deng; Guangyu Zhao; Yonghui Zhang; Yue Wang; Yusen Zhou; Wenjie Tan; Honglin Xu
Journal:  Vaccine       Date:  2012-10-29       Impact factor: 3.641

8.  Nanoscale Coordination Polymer Based Nanovaccine for Tumor Immunotherapy.

Authors:  He Zhao; Jun Xu; Yan Li; Xinxian Guan; Xiao Han; Yunyun Xu; Huiting Zhou; Rui Peng; Jian Wang; Zhuang Liu
Journal:  ACS Nano       Date:  2019-11-13       Impact factor: 15.881

9.  Split inactivated COBRA vaccine elicits protective antibodies against H1N1 and H3N2 influenza viruses.

Authors:  James D Allen; Satyajit Ray; Ted M Ross
Journal:  PLoS One       Date:  2018-09-28       Impact factor: 3.240

10.  Influenza pandemics of the 20th century.

Authors:  Edwin D Kilbourne
Journal:  Emerg Infect Dis       Date:  2006-01       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.